Navigation Links
Vion Reports 2007 Fourth Quarter and Year-End Results
Date:3/17/2008

mpany implemented a one-for-ten reverse split of all outstanding shares of its common stock and a corresponding decrease in the number of shares of authorized common stock. Share and per share amounts contained herein are provided on a post-split basis.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, particularly Cloretazine(R) (VNP40101M), delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to c
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
2. Renovis Reports Fourth Quarter and Full Year 2007 Financial Results
3. Warner Chilcott Reports the Death of Its Director James Andress
4. Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
5. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
6. Unigene Restates Policy on Analyst Reports
7. NPS Pharmaceuticals Reports 2007 Financial Results
8. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
9. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
10. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
11. MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Louis, MO (PRWEB) July 28, 2014 ... software, and services that bring the power of genomics ... the inaugural Appistry Pipeline Challenge . , ... Bell, president of the National Center for Genome Resources, ... Mercy Hospitals and Clinics of Kansas City. Rounding out ...
(Date:7/28/2014)... 2014  InterMune, Inc. (NASDAQ: ITMN ) ... 2014 financial results at the close of the U.S. ... and webcast will be hosted by InterMune at 4:30 ... investors and others may participate in the conference call ... ID#21728775. A replay of the webcast and teleconference will be ...
(Date:7/28/2014)... The National Model Aviation Museum, located at the ... announce that it has been granted full civilian museum ... Air Force. , The certification is the culmination of ... with an on-site inspection by Sarah Sessions, Museum Certification ... National Museum of the United States Air Force , ...
(Date:7/25/2014)... , July 25, 2014 Amgen (NASDAQ: ... today declared a $0.61 per share dividend for the ... on Sept. 5, 2014, to all stockholders of record ... 2014.  About Amgen Amgen is committed ... from serious illnesses by discovering, developing, manufacturing and delivering ...
Breaking Biology Technology:Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2InterMune to Release Second Quarter Financial Results on August 6 2AMA’s National Model Aviation Museum Granted Full Civilian Museum Certification by the National Museum of the United States Air Force 2Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3
... Transgenomic, Inc. (OTC/BB: TBIO) today reported financial results for ... business update. Second Quarter Financial ResultsNet sales ... increase of 50 percent compared with $5.1 million for the ... 59 percent of net sales, compared with gross profit of ...
... BETHESDA, Md., Aug. 11, 2011 The American College ... new ACMG Online Live Learning Center , which ... health care professionals. This valuable, on-demand resource brings the ... live learning offerings such as the Genetics Review Course ...
... GNVC ) today announced that its Board of ... through the adoption of a new Rights Agreement. The new ... 2011, which is the date that GenVec,s existing Rights Agreement ... in connection with the expiration of the existing Rights Agreement ...
Cached Biology Technology:Transgenomic Reports Second Quarter Financial Results 2Transgenomic Reports Second Quarter Financial Results 3Transgenomic Reports Second Quarter Financial Results 4Transgenomic Reports Second Quarter Financial Results 5Transgenomic Reports Second Quarter Financial Results 6Transgenomic Reports Second Quarter Financial Results 7Transgenomic Reports Second Quarter Financial Results 8Transgenomic Reports Second Quarter Financial Results 9ACMG Announces New Online Live Learning Center: Will Bring Genetics and Genomics Education to Varied Health Professionals 2GenVec Renews Stockholder Rights Plan 2GenVec Renews Stockholder Rights Plan 3
(Date:7/28/2014)... MIT professor John Essigmann and colleagues from the University of ... thought if they could induce the virus to mutate uncontrollably, ... a strategy that our immune system uses against many ... caused HIV to mutate at an enhanced rate, as expected. ... a small clinical trial reported in 2011. In a new ...
(Date:7/28/2014)... wild relative of the domestic tomato, has been published ... headed by Professors Neelima Sinha and Julin Maloof at ... genome information may help breeders produce tastier, more stress-tolerant ... journal Nature Genetics , was lead by Bjrn ... UC Davis labs carried out work on the transcriptome ...
(Date:7/28/2014)... suggest two ways to effectively address the problem that birth ... compared to women of a normal body mass index. , ... as the population has increased in weight, concern has grown ... have consistently found that obesity has a negative impact on ... how well the pill prevents pregnancy. , "Birth ...
Breaking Biology News(10 mins):Forced mutations doom HIV 2Forced mutations doom HIV 3Forced mutations doom HIV 4Strategies identified to improve oral contraceptive success with obese women 2
... University of Iowa researchers have found high levels of ... Indiana Harbor and Ship Canal (IHSC) in East Chicago, Ind. ... IHSC is scheduled to be dredged in spring 2012 to ... area of southern Lake Michigan. The study, published online ...
... time when Dr. Roberto Bolli received word that he ... National Institutes of Health for one research project, five ... University of Louisville have reached the successful endpoint of ... Institute of the NIH has funded Bolli,s program project ...
... The diamondback moth, Plutella xylostella , is ... has developed resistance to many chemical and biological pesticides, ... is approximately US$1billion annually. In a new article ... , researchers from Australia have identified the genes expressed ...
Cached Biology News:Researchers find high levels of toxic PCBs in Indiana Harbor and Ship Canal 2Researchers find high levels of toxic PCBs in Indiana Harbor and Ship Canal 3Louisville researcher awarded $12.8 million NIH grant renewal for adult stem cell project 2Louisville researcher awarded $12.8 million NIH grant renewal for adult stem cell project 3Diamondback moth host-parasite interaction unraveled 2